STAT
FEBRUARY 4, 2025
The National Cancer Institute (NCI) has had a taxpayer-funded drug development program for nearly 70 years, initiated at a time when there was no private investment in oncology drugs. taxpayers should stop funding clinical trials of industry-owned drugs. At this stage, U.S. Keytruda).
European Pharmaceutical Review
JULY 13, 2023
3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. 2,10 This data can help to inform the optimal drug candidates to take forward into clinical trials and inform pre-clinical research to iteratively develop medications for different clinical indications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 4, 2024
4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 2005 [cited 2024May]. 2012/1916). BMB Reports. 2017;50(3):111–6.
pharmaphorum
APRIL 13, 2021
She is an experienced executive in drug development and has over 30 years’ experience in the biotechnology and pharmaceutical industry. from September 2005 to August 2008. from September 2005 to August 2008. About the author. Dr Cindy Jacobs is president and chief medical officer of Achieve Life Sciences.
pharmaphorum
JUNE 8, 2022
Since 2005, the number of peer-reviewed sleep journals has more than tripled , reflecting both the increased importance placed on a sufficient level of sleep and an ability to test patients in a more convenient manner. Why is sleep being discussed more? Novel digital endpoints.
FDA Law Blog: Biosimilars
JUNE 11, 2023
Clissold — In May 2023, CDER and CBER published a draft guidance titled “Pediatric Drug Development: Regulatory Considerations – Complying with the Pediatric Research Equity Act [“PREA”] and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act [“BPCA”]” (the “Draft Guidance”).
STAT
DECEMBER 13, 2024
Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short of goals set by the United Nations and most of the increase came from just two organizations, according to a new report.
Expert insights. Personalized for you.
291 
Let's personalize your content